Compound reference
Oxytocin
Also known as Pitocin
Oxytocin is two things at once — an FDA-approved injectable obstetric drug (Pitocin) given by IV for labor and postpartum bleeding, and an investigational intranasal "social/bonding" agent whose largest, most rigorous trial (in autism) was null. The popular intranasal use is mechanistically motivated but not backed by convincing human outcome data.
- CAS
- 50-56-6
- Molar mass
- ≈1007 g/mol
- Sequence
- Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (1→6 disulfide) — a 9-residue cyclic neuropeptide
- Half-life
- ≈1–6 min in plasma (IV)
Approved prescription medicine for labeled obstetric uses; social/behavioral claims require careful sourcing.
Mode of action
Oxytocin is a nine-amino-acid cyclic neuropeptide, synthesised in the hypothalamus and released from the posterior pituitary, that signals through the oxytocin receptor (OXTR). It has two quite different lives. Peripherally it is a classical hormone: it contracts uterine smooth muscle in labor and drives milk let-down. Centrally it is the prototypical "social" neuropeptide, modulating social recognition, bonding, trust and salience — rodent work localises a core of this to OXTR signalling in the medial amygdala, which is necessary and sufficient for social recognition in mice. Popular interest in oxytocin rests on that central role, and on the hope that intranasal delivery can reach the brain to influence human social and affective behaviour — a delivery assumption that remains debated.
Main intended effect
Two distinct goals, depending on formulation. The approved injectable drug induces or augments labor and controls postpartum uterine bleeding. The investigational, typically intranasal use aims to modulate social cognition, bonding, anxiety and psychiatric symptoms.
Areas of interest
Obstetrics is the settled, approved domain. The active frontier — and the source of most consumer interest — is neuropsychiatry: autism spectrum disorder, social anxiety, mood and depression, and bonding/relationship effects. A translational literature links the rodent social-circuit biology to these human hypotheses.
Evidence for intended effects
The two domains could hardly differ more in evidence quality. For its obstetric indications, oxytocin (Pitocin) is long-established standard care, and a large meta-analysis (61 RCTs, ~69,000 participants) found a tolerability profile at least as good as other uterotonics. For social and psychiatric uses the record is mixed and, where it matters most, disappointing: the largest and most rigorous trial — a multicenter phase 2 RCT of intranasal oxytocin in 290 children and adolescents with autism (NEJM 2021) — was null on core social symptoms. Smaller studies are more encouraging but much weaker: an early adult-autism pilot (2012) showed only exploratory secondary-measure signals, and a recent pilot RCT (Ellenbogen, 2024, n=23) found intranasal oxytocin improved outcomes when added to psychotherapy for depression — promising but tiny and underpowered. The mechanism is real; reliable human behavioural benefit from exogenous oxytocin is not yet demonstrated.
| Strand | What exists | Tier |
|---|---|---|
| Obstetric (labor, postpartum bleeding) | Approved drug; large safety meta-analysis | Established / approved |
| Social-recognition mechanism | Rodent medial-amygdala studies | Well characterized (preclinical) |
| Autism / social cognition | Definitive phase 2 RCT — null; small pilots mixed | Largely negative |
| Depression (psychotherapy adjunct) | Single small pilot RCT (positive) | Preliminary |
Studied amounts (literature dosing context)
The approved drug, Pitocin, is given only by controlled intravenous infusion under hospital supervision, titrated to uterine response. Research on social and psychiatric effects has typically used intranasal oxytocin around 24 IU (autism trials have used roughly 24–48 IU daily). There is no approved intranasal oxytocin product for psychiatric or social use, and this page does not provide dosing guidance.
Safety and regulatory status
Injectable oxytocin (Pitocin) is FDA-approved for medically indicated labor induction and augmentation, adjunctive management of incomplete or inevitable abortion, and postpartum control of bleeding — explicitly not for elective induction. It is a hospital-only drug because its serious risks (uterine hyperstimulation and rupture, postpartum hemorrhage, maternal water intoxication, fetal bradycardia) require monitoring. Intranasal oxytocin used in research is generally well tolerated over the short term, but it is not approved for any psychiatric, social, or "bonding" indication, and intranasal or sublingual oxytocin products sold for those purposes are unregulated and of unverified content.
Sources
The effects of intranasal oxytocin on the efficacy of psychotherapy for major depressive disorder: a pilot randomized controlled trial
Ellenbogen and colleagues conducted a double-blind, placebo-controlled pilot RCT testing intranasal oxytocin as an adjunct to psychotherapy in 23 community-recruited adults (ages 18-50, 12 female) with mild-to-moderate major depressive disorder, randomized to oxytocin (n=12) or placebo (n=11). Participants self-administered 24 IU intranasal oxytocin or placebo 30 minutes before each of 16 weekly sessions of interpersonal therapy (IPT), with assessment through 6 months post-treatment. Multilevel modeling found a significant oxytocin effect on the negative slope of depressive symptoms over time (p<0.05), with medium-to-large effect sizes at post-treatment (Cohen's d=0.75) and follow-up (d=0.82); oxytocin also improved the patient-rated therapeutic alliance at the first session (d=0.89), and agreement on therapeutic goals mediated the link between oxytocin and symptom improvement. As a small pilot it was underpowered for the mediation analyses, was limited to a community sample with mild-to-moderate depression, and its findings are specific to IPT, so the results are hypothesis-generating and require replication in adequately powered trials. Oxytocin is not an approved treatment for depression.
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Sikich and colleagues ran a 24-week, multicenter, double-blind, placebo-controlled phase 2 trial of intranasal oxytocin in children and adolescents 3-17 years of age with autism spectrum disorder; 290 of 355 screened participants were enrolled and randomized 1:1 to oxytocin or placebo at a total target dose of 48 IU daily. The primary outcome was least-squares mean change from baseline on the Aberrant Behavior Checklist modified Social Withdrawal subscale (ABC-mSW, 13 items, 0-39, higher = less social interaction). Change was -3.7 in the oxytocin group versus -3.5 with placebo, a non-significant between-group difference, and no significant differences emerged on secondary measures of social or cognitive functioning. Adverse events were similar across groups. This is the largest and most definitive oxytocin-for-autism RCT to date and its null primary result tempers earlier single-dose social-cognition findings; the evidence does not support chronic intranasal oxytocin for core social symptoms in pediatric ASD.
Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial
Anagnostou and colleagues conducted a randomized, double-blind, placebo-controlled parallel pilot trial in 19 adults with autism spectrum disorder (16 male, mean age 33.2 years; 10 oxytocin, 9 placebo) given 24 IU intranasal oxytocin or placebo twice daily for 6 weeks. Primary outcomes (Diagnostic Analysis of Nonverbal Accuracy, Repetitive Behavior Scale-Revised, Clinical Global Impression) showed no significant improvement after baseline correction. Secondary measures improved on the Reading-the-Mind-in-the-Eyes Test (p=0.002, d=1.2) and a quality-of-life emotion subscale (p=0.031, d=0.84); oxytocin was well tolerated with no serious adverse effects. The very small sample and exploratory secondary signals make this hypothesis-generating rather than confirmatory, and its positive social-cognition findings were not replicated by larger later trials.
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, Domes, Kirsch, and Heinrichs review the role of oxytocin and the structurally related vasopressin in human social functioning, drawing together behavioral studies, genetic variation in neuropeptide signaling, and functional neuroimaging. The authors describe how oxytocin modulates social cognition, trust, and amygdala-dependent fear circuitry, and frame both peptides as emerging treatment targets for disorders of social dysfunction. They specifically discuss autism, social anxiety disorder, borderline personality disorder, and schizophrenia, and highlight potential synergy with psychotherapy. As a narrative review it synthesizes mechanism and early translational evidence rather than weighing pooled clinical efficacy, and predates the larger negative oxytocin-for-autism RCTs.
Oxytocin in the medial amygdala is essential for social recognition in the mouse
Ferguson, Aldag, Insel, and Young used oxytocin knockout (OTKO) mice to localize the neural substrate of social recognition. OTKO mice failed to recognize familiar conspecifics across repeated social exposures despite intact olfactory and spatial learning. Site-specific oxytocin injection into the medial amygdala before, but not after, the initial encounter restored social recognition, whereas olfactory-bulb injection did not, and an oxytocin-receptor antagonist in the medial amygdala of wild-type mice produced a recognition deficit. The authors conclude oxytocin-receptor activation in the medial amygdala is necessary and sufficient for social recognition. This is a rodent mechanistic study; the timing- and region-specificity informs human social-cognition hypotheses but does not establish behavioral effects of exogenous oxytocin in people.
PITOCIN (oxytocin) injection — FDA Prescribing Information (DailyMed)
The FDA-approved Pitocin (oxytocin injection, USP) label, distributed via DailyMed (labeler Par Pharmaceutical), documents the synthetic nonapeptide's approved obstetric uses: antepartum initiation or improvement of uterine contractions for medically indicated labor induction, stimulation of labor in uterine inertia, adjunctive management of incomplete or inevitable abortion, and postpartum control of uterine bleeding and hemorrhage. The label states oxytocin should be given only by controlled intravenous infusion under hospital supervision and explicitly is not indicated for elective induction of labor given inadequate benefit-risk data. Serious risks listed include uterine rupture, postpartum hemorrhage, and water intoxication for the mother, and bradycardia or CNS injury for the fetus. This is a regulatory labeling document defining approved indications and warnings, not a study, and reflects the revision shown on the DailyMed record.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=969d5b35-0add-4c23-9605-6a5b6ab65c95
Side-effects of oxytocin in postpartum hemorrhage: a systematic review and meta-analysis
Zeng and colleagues pooled 61 randomized controlled trials enrolling 68,834 participants to characterize the adverse-event profile of oxytocin used for postpartum hemorrhage, searching Web of Science, Embase, PubMed, ScienceDirect, the Cochrane Library, and ClinicalTrials.gov through September 2021. Across 27 reported side-effect types, oxytocin showed significantly lower risk than non-oxytocin uterotonic comparators for shivering (RR 0.31, 95% CI 0.23-0.41), fever (RR 0.27, 95% CI 0.20-0.37), and diarrhea (RR 0.48, 95% CI 0.35-0.66), with no increased risk for vomiting, nausea, headache, flushing, or dizziness. The favorable signals are largely relative to other uterotonics (e.g., misoprostol, ergometrine) rather than placebo, so the comparison reflects head-to-head tolerability in the obstetric setting and does not address rare serious events such as water intoxication or uterine hyperstimulation.